Maven Clinic: Women's Health in the Digital Age

Ariel D.  Stern; Sarah  Mehta

Case | HBS Case Collection | March 2020

Maven Clinic: Women's Health in the Digital Age

Abstract

In late 2017, Kate Ryder, the founder and CEO of digital women’s health telemedicine company Maven Clinic, faced an important decision. Maven offered both a direct to consumer (D2C) product that anyone could use to book virtual appointments with health practitioners across a range of services and specialties for a fee, and an enterprise product—the Maven Family Benefits platform—which it sold to large employers as an employee benefit. Since founding Maven in 2014, Ryder had believed that the way to achieve true impact and scale is to work within that system, but the most effective strategy for pursuing enterprise customers was an open question. She considered her options.

Keywords: Business Growth and Maturation; Business Model; Business Startups; Entrepreneurship; Health; Health Care and Treatment; Strategy; Technology; Software; Health Industry; Technology Industry; United States;

Language: English

Format: Print

21 pages

Educators Purchase

Citation:

Stern, Ariel D., and Sarah Mehta. "Maven Clinic: Women's Health in the Digital Age." Harvard Business School Case 620-035, March 2020.

In 2019, the co-founders of the Swedish medical start-up 1928 Diagnostics, CEO Dr. Kristina Lagerstedt and COO Dr. Susanne Staaf, had to pick the right business model to commercialize their novel technology to hospitals and health care providers. Developed in partnership with research hospitals to help fight the global antibiotic resistance crisis, the firm’s cloud-based technology platform helped partners identify resistant genes and mutations in bacteria more quickly and accurately, allowing for easier outbreak cluster tracking in support of hospital infection control management, as well as better diagnostics and antibiotic selection. By 2019, they had raised $5 million, employed 16 people, and had their tool deployed at 24 partner sites in 10 different countries. Their decisions on which markets to focus on and with which business model would crucially impact the young firm’s chances at successfully converting existing users and attracting new clients.

In 2019, Fitbit lost its leadership in the wearable sensor market to Apple and to cheaper alternatives.
Why did it lose its market position?
How will the proposed acquisition affect it and Google?

Emerging gene therapy and gene-editing technologies will have a growing impact on patient lives and health-care delivery. We analyzed a decade of data on clinical trials and venture capital investments to understand the likely trajectory of genetically focused therapies in the years ahead. The number of clinical trials and venture capital deals increased substantially from 2006–2017. We observed particularly notable growth in both industry-sponsored trials and trials involving specialty fields of drug development, including oncology, neurology, hematology, ophthalmology, and neurology. As the number of gene-therapy and gene-editing technologies continues to grow, we expect that such therapies will have a significant and heterogeneous impact on health-care delivery, including a shifting of resources from chronic disease management to more intense acute episodic care, an increase in the complexity of required intellectual property and manufacturing know-how, and the potential expansion of biopharmaceutical companies into service-based business models.

Faculty & Research

Maven Clinic: Women's Health in the Digital Age

Abstract

Citation:

About the Author

More from the Author